Evogene
EVGN
29 hedge funds and large institutions have $3.04M invested in Evogene in 2024 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 7 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
0.73% less ownership
Funds ownership: 8.74% → 8.01% (-0.73%)
12% less funds holding
Funds holding: 33 → 29 (-4)
18% less capital invested
Capital invested by funds: $3.69M → $3.04M (-$653K)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$79.8K |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$17.9K |
| 3 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$13.1K |
| 4 |
SIGI
Susquehanna International Group (Ireland)
Dublin,
Ireland
|
+$11.1K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$9.64K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
-$293K |
| 2 |
CCM
Connective Capital Management
Palo Alto,
California
|
-$84K |
| 3 |
Millennium Management
New York
|
-$28.6K |
| 4 |
JP Morgan Chase
New York
|
-$21K |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$12.1K |
EVGN Hedge Fund Activity: Q1 2024 in Review
29 of the 6,959 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q1 2024, worth a combined $3.04M — down 18% from $3.69M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of EVGN and 4 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 8 added.
The largest buyer was Morgan Stanley, adding an estimated $79.8K. The largest seller was Walleye Capital, exiting entirely with an estimated $293K sold.
- 29 institutional investors held Evogene (EVGN) as of Q1 2024, down from 33 in Q4 2023.
- Funds reported $3.04M of Evogene stock for Q1 2024, down 18% quarter-over-quarter.
- 4 funds opened new Evogene positions in Q1 2024 and 7 closed out, a net change of -3 holders.
- The largest Evogene buyer in Q1 2024 was Morgan Stanley, an estimated $79.8K added.
- The largest Evogene seller in Q1 2024 was Walleye Capital, an estimated $293K sold.
Based on aggregated 13F filings for Q1 2024.